Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuraptive Therapeutics Inc.

www.neuraptive.com

Latest From Neuraptive Therapeutics Inc.

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter. 

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Consumables, Central Supplies
    • Surgical Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Neuraptive Therapeutics Inc.
  • Senior Management
  • David M Jackson, PhD, CEO
    Carter Freeman, CFO
    Stefan Proniuk, PhD, Chief Dev. Officer
    Evan Tzanis, EVP, Head R&D
  • Contact Info
  • Neuraptive Therapeutics Inc.
    Phone: (303) 736-9657
    2697 Trail Ridge Dr., West
    Lafayette, CO 80026
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register